Plasma Riboflavin Level is Associated with Risk, Relapse, and Survival of Esophageal Squamous Cell Carcinoma

Nutrition and Cancer

Volumn 69, Issue 1, 2017, Pages 21-28

  Li, Shan Shan ^a   Xu, Yi Wei ^a,b   Wu, Jian Yi ^a   Tan, Hua Zhen ^a   Wu, Zhi Yong ^c   Xue, Yu Jie ^a   Zhang, Jian Jun ^a   Li, En Min ^a   Xu, Li Yan ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b CANCER HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^c SHANTOU CENTRAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RIBOFLAVIN; CARRIER PROTEIN; SLC52A3 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GROUPS BY AGE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; SURVIVAL TIME; TUMOR INVASION; TUMOR VOLUME; VITAMIN BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; ESOPHAGUS TUMOR; GENETICS; KAPLAN MEIER METHOD; MORTALITY; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RIBOFLAVIN;

EID: 84999622537     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2017.1247890     Document Type: Article

References (40)

1. Subramanian VS, Subramanya SB, Rapp L, Marchant JS, Ma TY, et al.:Differential expression of human riboflavin transporters −1, −2, and −3 in polarized epithelia:a key role for hRFT-2 in intestinal riboflavin uptake. Biochim Biophys Acta 1808, 3016–3021, 2011.
2. He Y, Ye L, Shan B, Song G, Meng F, et al.:Effect of riboflavin-fortified salt nutrition intervention on esophageal squamouscell carcinoma. Asian Pac J Cancer Prev 10, 619–622, 2009.
3. Yao Y, Yonezawa A, Yoshimatsu H, Masuda S, Katsura T, et al.:Identification and comparative functional characterization of a new human riboflavin transporter hRFT3 expressed in the brain. J Nutr 140, 1220–1226, 2010.
4. Nabokina SM, Subramanian VS, and Said HM, :Effect of clinical mutations on functionality of the human riboflavin transporter-2 (hRFT-2). Mol Genet Metab 105, 652–657, 2012.
5. Subramanian VS1, Rapp L, Marchant JS, and Said HM, :Role of cysteine residues in cell surface expression of the human riboflavintransporter-2 (hRFT2) in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 301, 2011.
6. Pangrekar J, Krishnaswamy K, and Jagadeesan V, :Effects of riboflavin deficiency and riboflavin administration on carcinogen-DNA binding. Food Chem Toxicol 31, 745–750, 1993.
7. Kweon SS, Shu XO, Xiang Y, Yang G, Ji BT, et al.:One-carbon metabolism dietary factors and distal gastric cancer risk in chinese women. Cancer Epidemiol Biomarkers Prev 23, 1374–1382, 2014.
8. Bassett JK, Baglietto L, Hodge AM, Severi G, Hopper JL, et al.:Dietary intake of B vitamins and methionine and breast cancer risk. Cancer Causes Control 24, 1555–1563, 2013.
9. Zschabitz S, Cheng TY, Neuhouser ML, Zheng Y, Ray RM, et al.:B vitamin intakes and incidence of colorectal cancer:results from the Women's Health Initiative Observational Study cohort. Am J Clin Nutr 97, 332–343, 2013.
10. Takata Y, Cai Q, Beeghly-Fadiel A, Li H, Shrubsole MJ, et al.:Dietary B vitamin and methionine intakes and lung cancer risk among female never smokers in China. Cancer Causes Control 23, 1965–1975, 2012.
11. Siassi F, Ghadirian P, :Riboflavin deficiency and esophageal cancer:a case control-household study in the Caspian Littoral of Iran. Cancer Detect Prev 29, 464–469, 2005.
12. Ainiwaer J, Tuerhong A, Hasim A, Chengsong D, Liwei Z, et al.:Association of the plasma riboflavin levels and riboflavin transporter (C20orf54) gene statuses in Kzark esophageal squamous cell carcinoma patients. Mol Biol Rep 40, 3769–3775, 2013.
13. Li LY, Li EM, Wu ZY, Cao HH, Shen JH, et al.:Overexpression of GRB2 is correlated with lymph node metastasis and poorprognosis in esophageal squamous cell carcinoma. Int J Clin Exp Pathol 7, 3132–3140, 2014.
14. Song Y, Li L, Ou Y, Gao Z, Li E, et al.:Identification of genomic alterations in oesophageal squamous cell cancer. Nature 509, 91–95, 2014.
15. Wang KJ, Yang JX, Shi JC, Deng SY, Cao XQ, et al.:Genetic epidemiological analysis of esophageal cancer in high-incidence areas of China. Asian Pac J Cancer Prev 15, 9859–9863, 2014.
16. Xu Y, Yu X, Chen Q, and Mao W, :Neoadjuvant versus adjuvant treatment:which one is better for resectable esophageal squamous cell carcinoma. World J Surg Oncol 10, 1477–7819, 2012.
17. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al.:Global cancer statistics. CA Cancer J Clin 61, 69–90, 2011.
18. Sun LL, Wu JY, Wu ZY, Shen JH, Xu XE, et al.:A three-gene signature and clinical outcome in esophageal squamous cell carcinoma. Int J Cancer 136, 2015.
19. Li XM, Peng XQ, Huang J, Wang WP, Zhang P, et al.:Changes of five-year survival rates in patients with esophageal squamous cell carcinoma from 1973 to 2005. Cancer Res Prevent Treat 41, 6, 2014.
20. Min S, Dong-Ping T, Xiao-Yun L, Jun-Kai S, Yi-Fan L, et al.:Four case reports of families with esophageal cancer in a high-risk region on the Guangdong Chaoshan coast of China. Dis Esophagus 15, 257–261, 2002.
21. Ji AF, Wei W, Wang JS, Wei ZB, Lian CH, et al.:A comparison and significance of plasma riboflavin levels in patients with esophageal squamous cell carcinoma versus Linzhou healthy migrants in Changzhi of Shanxi. Zhonghua Nei Ke Za Zhi 50, 1048–1050, 2011.
22. Premkumar VG, Yuvaraj S, Sathish S, Shanthi P, and Sachdanandam P, :Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy. Vascul Pharmacol 48, 191–201, 2008.
23. Camp RL1, Dolled-Filhart M, and Rimm DL, :X-tile:a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10, 7252–7259, 2004.
24. Yonezawa A1, Masuda S, Katsura T, Inui K, :Identification and functional characterization of a novel human and rat riboflavin transporter,RFT1. Am J Physiol Cell Physiol 295, 2008.
25. Yao Y, Yonezawa A, Yoshimatsu H, Masuda S, Katsura T, et al.:Identification and comparative functional characterization of a new humanriboflavin transporter hRFT3 expressed in the brain. J Nutr 140, 1220–1226, 2010.
26. Yamamoto S, Inoue K, Ohta KY, Fukatsu R, Maeda JY, et al.:Identification and functional characterization of rat riboflavin transporter 2. J Biochem 145, 437–443, 2009.
27. Intoh A, Suzuki N, Koszka K, and Eggan K, :SLC52A3, A Brown-Vialetto-van Laere syndrome candidate gene is essential for mouse development, but dispensable for motor neuron differentiation. Hum Mol Genet 13, 2016.
28. Song Y, Li L, Ou Y, Gao Z, Li E, et al.:Identification of genomic alterations in oesophageal squamous cell cancer. Nature 509, 91–95, 2014.
29. Jiang XR, Yu XY, Fan JH, Guo L, Zhu C, et al.:RFT2 is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenesis by sustaining cell proliferation and protecting against cell death. Cancer Lett 353, 78–86, 2014.
30. Wang LD, Zhou FY, Li XM, Sun LD, Song X, et al.:Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. Nat Genet 42, 759–763, 2010.
31. Dura P, Bregitha CV, te Morsche RH, Roelofs HM, Kristinsson JO, et al.:GWAS-uncovered SNPs in PLCE1 and RFT2 genes are not implicated in Dutch esophageal adenocarcinoma and squamous cell carcinoma etiology. Eur J Cancer Prev 22, 417–419, 2013.
32. Gu H, Ding G, Zhang W, Liu C, Chen Y, et al.:Replication study of PLCE1 and C20orf54 polymorphism and risk of esophageal cancer in Chines population. Mol Biol Rep 39, 9105–9111, 2012.
33. Ji A, Wang J, Yang J, Wei Z, Lian C, et al.:Functional SNPs in human C20orf54 gene influence susceptibility to esophageal squamous cell carcinoma. Asian Pac J Cancer Prev 12, 3207–3212, 2011.
34. Otero JA, Miguel V, González-Lobato L, García-Villalba R, Espín JC, et al.:Effect of bovine ABCG2 polymorphism Y581S SNP on secretion into milk of enterolactone, riboflavin and uric acid. Animal 10, 238–247, 2016.
35. Huang L, Lu Q, Han Y, Li Z, Zhang Z, et al.:ABCG2/V-ATPase was associated with the drug resistance and tumor metastasis of esophageal squamous cancer cells. Diagn Pathol 7, 1746–1596, 2012.
36. Tsunoda S, Okumura T, Ito T, Kondo K, Ortiz C, et al.:ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma. Oncology 71, 251–258, 2006.
37. Chen L, Feng L, Jiang WD, Jiang J, Wu P, et al.:Dietary riboflavin deficiency decreases immunity and antioxidant capacity, and changes tight junction proteins and related signaling molecules mRNA expression in the gills of young grass carp (Ctenopharyngodon idella). Fish Shellfish Immunol 45, 307–320, 2015.
38. Grivennikov SI, Greten FR, and Karin M, :Immunity, inflammation, and cancer. Cell 140, 883–899, 2010.
39. Roca H, and McCauley LK, :Inflammation and skeletal metastasis. Bonekey Rep 4, 2015.
40. Chaffer CL, and Weinberg RA, :A perspective on cancer cell metastasis. Science 331, 1559–1564, 2011.